Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia

Summaries for Thrombocytopenia

KEGG : 37
Thrombocytopenia is defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. Inherited syndromes are relatively rare causes of thrombocytopenia, but some genes underlying these disorders have been elucidated. Some inherited syndromes predispose to the development of bone marrow failure or leukemia. For example, familial platelet disorder with associated myeloid malignancy (FPDMM) is characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.

MalaCards based summary : Thrombocytopenia is related to thrombocytopenia 1 and thrombocytopenia 2. An important gene associated with Thrombocytopenia is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Tight junction and Response to elevated platelet cytosolic Ca2+. The drugs Bivalirudin and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and lung, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A blood platelet disease characterized by low a platelet count in the blood.

PubMed Health : 63 About thrombocytopenia: Thrombocytopenia (THROM-bo-si-to-PE-ne-ah) is a condition in which your blood has a lower than normal number of blood cell fragments called platelets (PLATE-lets). Platelets are made in your bone marrow along with other kinds of blood cells. They travel through your blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes (THROM-bo-sites) because a clot also is called a thrombus.

Wikipedia : 75 Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as... more...

Related Diseases for Thrombocytopenia

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia

Diseases related to Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1486)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia 1 35.1 WAS HOXA11 GATA1
2 thrombocytopenia 2 34.7 MASTL ANKRD26
3 thrombocytopenia-absent radius syndrome 34.6 RBM8A MPL GP1BA GATA1 ANKRD26
4 autosomal thrombocytopenia with normal platelets 34.3 MASTL CYCS
5 myh-9 related disease 34.0 MYH9 GP1BA ANKRD26
6 platelet disorder, familial, with associated myeloid malignancy 33.4 ETV6 ANKRD26
7 thrombocytopenia due to platelet alloimmunization 33.3 MYH9 MPL ITGB3 ITGA2B ITGA2 GP9
8 thrombocytopenic purpura, autoimmune 33.2 MPL ITGB3 ITGA2B IL11 GP1BA
9 fetal and neonatal alloimmune thrombocytopenia 33.2 ITGB3 ITGA2B ITGA2 GP1BB GP1BA
10 primary thrombocytopenia 32.6 MYH9 MPL ITGB3 ITGA2B ITGA2 GP1BA
11 gray platelet syndrome 32.6 MASTL GP9 GATA1
12 pseudo-von willebrand disease 31.5 GP9 GP1BB GP1BA
13 bleeding disorder, platelet-type, 16 31.1 ITGB3 ITGA2B
14 bernard-soulier syndrome 31.1 MYH9 ITGB3 ITGA2B ITGA2 GP9 GP1BB
15 aplastic anemia 30.8 MPL ITGA2B IL11 GATA1
16 purpura 30.6 MPL ITGB3 ITGA2B GP1BB ADAMTS13
17 autosomal dominant macrothrombocytopenia 30.3 MYH9 ITGB3 ITGA2B GP1BB GP1BA
18 essential thrombocythemia 30.0 MPL ITGB3 ITGA2B IL11 GP1BA GATA1
19 aspirin resistance 29.9 ITGB3 ITGA2
20 hematologic cancer 29.9 MPL IL11 ETV6 CYCS
21 megakaryocytic leukemia 29.8 ITGA2B IL11 GATA1
22 hemorrhagic disease 29.7 MPL ITGA2B GP1BA ADAMTS13
23 thrombasthenia 29.6 ITGB3 ITGA2B ITGA2 GP9 GP1BA
24 hemorrhagic cystitis 29.6 IL11 CYCS
25 blood platelet disease 29.6 WAS MYH9 MPL ITGB3 ITGA2B GP9
26 glanzmann thrombasthenia 29.4 ITGB3 ITGA2B ITGA2 GP9 GP1BA
27 myocardial infarction 29.3 ITGB3 ITGA2B ITGA2 GP1BA ADAMTS13
28 von willebrand disease, type 2 29.0 ITGB3 ITGA2B ITGA2 GP1BA ADAMTS13
29 velocardiofacial syndrome 28.7 GP9 GP1BB GP1BA
30 amegakaryocytic thrombocytopenia, congenital 12.7
31 heparin-induced thrombocytopenia 12.7
32 thrombocytopenia with beta-thalassemia, x-linked 12.7
33 thrombocytopenia, paris-trousseau type 12.6
34 dyserythropoietic anemia and thrombocytopenia 12.6
35 thrombocytopenia, x-linked, with or without dyserythropoietic anemia 12.6
36 thrombocytopenia 5 12.6
37 thrombocytopenia 3 12.6
38 radioulnar synostosis with amegakaryocytic thrombocytopenia 1 12.6
39 thrombocytopenia 4 12.6
40 hemangioma-thrombocytopenia syndrome 12.5
41 thrombocytopenia 6 12.5
42 radioulnar synostosis with amegakaryocytic thrombocytopenia 2 12.5
43 radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome 12.5
44 acquired amegakaryocytic thrombocytopenia 12.5
45 thrombocytopenia, anemia, and myelofibrosis 12.5
46 acquired thrombocytopenia 12.4
47 myh9 related thrombocytopenia 12.4
48 transient neonatal thrombocytopenia 12.4
49 multifocal lymphangioendotheliomatosis with thrombocytopenia 12.3
50 thrombocytopenia, cyclic 12.3

Graphical network of the top 20 diseases related to Thrombocytopenia:

Diseases related to Thrombocytopenia

Symptoms & Phenotypes for Thrombocytopenia

MGI Mouse Phenotypes related to Thrombocytopenia:

# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CYCS ETV6 GATA1 GP1BA HOXA11 ITGA2
2 hematopoietic system MP:0005397 9.97 ADAMTS13 CYCS ETV6 GATA1 GP1BA GP1BB
3 embryo MP:0005380 9.86 CYCS ETV6 GATA1 ITGA2B ITGB3 MASTL
4 homeostasis/metabolism MP:0005376 9.73 ADAMTS13 ANKRD26 ETV6 GATA1 GP1BA GP1BB
5 immune system MP:0005387 9.28 ADAMTS13 CYCS ETV6 GATA1 ITGA2B ITGB3

Drugs & Therapeutics for Thrombocytopenia

PubMed Health treatment related to Thrombocytopenia: 63

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding. If your condition is mild, you may not need treatment. A fully normal platelet count isn't necessary to prevent bleeding, even with severe cuts or accidents. Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition usually don't need treatment. If a reaction to a medicine is causing a low platelet count, your doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin-induced thrombocytopenia (HIT), stopping the heparin isn't enough. Often, you'll need another medicine to prevent blood clotting. If your immune system is causing a low platelet count, your doctor may prescribe medicines to suppress the immune system.

DrugBank drugs 16 :

(show all 6)
# Drug Name Indication DrugBank ID
1 Avatrombopag Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure [FDA label]. DB11995
2 Eltrombopag Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. DB06210
3 Fostamatinib Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label]. DB12010
4 Lusutrombopag Lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. DB13125
5 Oprelvekin Indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.[Label] DB00038
6 Romiplostim Treatment of chronic immune thrombocytopenic purpura. DB05332

Drugs for Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 552)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
Oprelvekin Approved, Investigational Phase 4 145941-26-0
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Sodium citrate Approved, Investigational Phase 4 68-04-2
Atorvastatin Approved Phase 4 134523-00-5 60823
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Acetaminophen Approved Phase 4 103-90-2 1983
Phylloquinone Approved, Investigational Phase 4 84-80-0
Abciximab Approved Phase 4 143653-53-6
Cefpirome Approved Phase 4 84957-29-9 5479539
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Tirofiban Approved Phase 4 144494-65-5 60947
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
21 Bemiparin Approved, Investigational Phase 4 91449-79-5
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Pancrelipase Approved, Investigational Phase 4 53608-75-6
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
Ethanol Approved Phase 4 64-17-5 702
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Lorazepam Approved Phase 4 846-49-1 3958
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Dalteparin Approved Phase 4 9005-49-6
Clarithromycin Approved Phase 4 81103-11-9 84029
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Enoxaparin Approved Phase 4 9005-49-6 772
Warfarin Approved Phase 4 81-81-2 6691 54678486
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Desirudin Approved Phase 4 120993-53-5
Ribavirin Approved Phase 4 36791-04-5 37542
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Tenecteplase Approved Phase 4 191588-94-0
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 1011)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
3 Randomized Double Blind Trial Comparing Heparin and Placebo as Additives to Continuous Infusion in Intensive Care Neonates for Prevention of Ventilation Unknown status NCT00196469 Phase 4 heparin
4 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
5 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Continuous Renal Replacement Therapy Patients Unknown status NCT02355873 Phase 4
6 A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention Unknown status NCT00407771 Phase 4 Tirofiban
7 Prospective Trial of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients With Chronic Allograft Nephropathy Unknown status NCT00999258 Phase 4 sirolimus
8 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
9 Bivalirudin PCI Registry in HIT/HITTS Patients Completed NCT00759083 Phase 4 bivalirudin
10 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
11 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
12 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
13 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
14 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
15 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
16 Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE) Completed NCT00913133 Phase 4 Desirudin
17 Bicentric Clinical Trial With in Vitro Experiments to Assess the Effect of Fibrinogen (FGTW) on Coagulation in Thrombocytopenia Completed NCT01955811 Phase 4 Administration of platelet concentrate and taking blood samples
18 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
19 Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process Completed NCT01789762 Phase 4
20 Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial Completed NCT01269112 Phase 4
21 International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings Completed NCT00622648 Phase 4 Enoxaparin;Placebo
22 A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
23 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
24 Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
25 Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3 Completed NCT00262054 Phase 4 Bivalirudin;Un-fractionated heparin
26 Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression Completed NCT00306397 Phase 4 Rapamycin
27 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
28 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
29 Comparison of Bivalirudin and Unfractioned Heparin in Elective Percutaneous Coronary Interventions Completed NCT00448461 Phase 4 heparin;bivalirudin
30 FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study Completed NCT00383136 Phase 4 tirofiban high-bolus dose regimen;Abciximab
31 Efficacy of Nebulized Heparin and Salbutamol in Mechanically Ventilated Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease: a Randomized Clinical Trial Completed NCT03333395 Phase 4 Nebulized heparin and salbutamol;Nebulized salbutamol
32 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
33 The Effect of Prasugrel as Compared to Clopidogrel on Platelet Function Immediately Following the Termination of Intravenous Bivalirudin in Patients Undergoing Percutaneous Coronary and Structural Cardiac Intervention Completed NCT01789814 Phase 4 Prasugrel;Clopidogrel
34 Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in HIV Co-infected Patients, Implemented in Public Hospitals in Thailand Completed NCT02247440 Phase 4 Peg-interferon + ribavirin under HIV physician supervision
35 A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting Completed NCT00169819 Phase 4 Abciximab
36 CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial Completed NCT01281033 Phase 4
37 Facilitation Through Abciximab By drOpping Infusion Line in Patients Undergoing Coronary Stenting. SYNergy With Clopidogrel at High Loading dOse Regimen Completed NCT00929279 Phase 4 bolus+infusion;abciximab bolus only regimen
38 Comparative Effectiveness of 30% Trisodium Citrate and Heparin Lock Solutions in Preventing Infection and Dysfunction of Hemodialysis Catheters: a Randomized Controlled Trial (CITRIM Trial) Completed NCT02563041 Phase 4 30% TSC;Heparin
39 Phase 4 Randomized, Controlled Study Comparing Sirolimus and Mycophenolate Mofetil to Prevent or Reverse Progression in Pediatric Renal Transplants With Chronic Allograft Nephropathy Completed NCT00188955 Phase 4 sirolimus
40 Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study Completed NCT03146858 Phase 4 Enoxaparin
41 Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation Completed NCT00331162 Phase 4 Alemtuzumab;Anti-Thymocyte Globulin
42 Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries: a Double Blind, Placebo-controlled Study Completed NCT03664037 Phase 4 Dexamethasone phosphate;Placebo
43 Venous Thromboembolism Prevention in the Morbidly Obese Medically Ill Patient: A Pharmacological Analysis of the Predictability of Prophylactic Weight-Based Enoxaparin Dosing. Completed NCT00585182 Phase 4 Enoxaparin 0.5 mg/kg once daily
44 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
45 Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Completed NCT00494247 Phase 4
46 Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants Completed NCT00288600 Phase 4 Intravenous Immunoglobulin;Normal saline solution
47 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
48 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
49 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
50 High-dose Use of Recombinant Human Thrombopoietin in Patients With Moderate or Severe Thrombocytopenia Induced by Chemotherapy Recruiting NCT03633019 Phase 4 rhTPO

Search NIH Clinical Center for Thrombocytopenia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Thrombocytopenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: thrombocytopenia

Genetic Tests for Thrombocytopenia

Genetic tests related to Thrombocytopenia:

# Genetic test Affiliating Genes
1 Thrombocytopenia 29

Anatomical Context for Thrombocytopenia

MalaCards organs/tissues related to Thrombocytopenia:

Liver, Bone, Lung, Bone Marrow, Myeloid, Breast, Testes

Publications for Thrombocytopenia

Articles related to Thrombocytopenia:

(show top 50) (show all 30310)
# Title Authors PMID Year
Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats. 9 38
19705256 2010
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 9 38
20175767 2010
Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. 9 38
20430179 2010
The prothrombotic potential of platelet factor 4. 9 38
20206875 2010
Agranulocytosis in dengue hemorrhagic fever: a neglected condition. 9 38
20462096 2010
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. 9 38
20181616 2010
Pharmacodynamic effects of haematopoietic cytokines: the view of a clinical oncologist. 9 38
20050838 2010
Proteinase-activated receptor (PAR1) polymorphic variant correlates with thrombocytopenia in Gaucher disease. 9 38
19969492 2010
Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. 9 38
20154285 2010
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. 9 38
20150385 2010
Serum thrombopoietin level and thrombocytopenia during the neonatal period in infants with Down's syndrome. 9 38
19675574 2010
A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers. 9 38
19740526 2010
A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13. 9 38
20121555 2010
Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations. 9 38
19451811 2010
Heparin-induced thrombocytopenia. 9 38
20059332 2010
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. 9 38
20203368 2010
Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. 9 38
19679353 2010
Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. 9 38
19709391 2010
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. 9 38
19847791 2010
Perspectives on RUNX genes: an update. 9 38
19830829 2009
Heparin induced thrombocytopenia in a patient with factor V Leiden following cardiac surgery. 9 38
19783545 2009
Infectious causes of chronic immune thrombocytopenia. 9 38
19932434 2009
An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. 9 38
19409826 2009
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura. 9 38
19786614 2009
Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene. 9 38
19337732 2009
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. 9 38
19671919 2009
Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni. 9 38
19118853 2009
Intracranial hemorrhage in dengue fever: management and outcome: a series of 5 cases and review of literature. 9 38
19328535 2009
[Two Crimean-Congo hemorrhagic fever cases without history of tick contact from Ankara region]. 9 38
20084924 2009
Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding. 9 38
19815879 2009
Buerger's disease and anticardiolipin antibodies. 9 38
19455050 2009
Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants. 9 38
19691693 2009
Thrombopoietin receptor agonists in the treatment of thrombocytopenia. 9 38
19553811 2009
Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies. 9 38
19497062 2009
Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. 9 38
19698012 2009
Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid. 9 38
19801810 2009
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. 9 38
19494352 2009
Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. 9 38
19473438 2009
Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. 9 38
19628164 2009
Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. 9 38
19572073 2009
[Catastrophic antiphospholipid syndrome complicated by cardiogenic shock - a case report]. 9 38
19650000 2009
Patterns of acquired bleeding disorders in a tertiary care hospital. 9 38
19520680 2009
Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. 9 38
19200137 2009
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. 9 38
19195684 2009
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. 9 38
19351959 2009
von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. 9 38
19187073 2009
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia. 9 38
19252138 2009
Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. 9 38
19336737 2009
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. 9 38
19207581 2009
Identification of a predictive biomarker for hematologic toxicities of gemcitabine. 9 38
19289617 2009

Variations for Thrombocytopenia

ClinVar genetic disease variations for Thrombocytopenia:

6 (show top 50) (show all 218)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 12:12037475-12037475 12:11884541-11884541
2 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 12:12038902-12038902 12:11885968-11885968
3 CYFIP1 ; NIPA1 ; NIPA2 ; TUBGCP5 GRCh37/hg19 15q11.2(chr15: 22765628-23300287) copy number loss Pathogenic 15:22765628-23300287 :0-0
4 46;X;inv(X)(p11.4q24)dn inversion Pathogenic
5 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 12:12037415-12037415 12:11884481-11884481
6 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1del short repeat Pathogenic rs786205154 12:12038855-12038859 12:11885921-11885925
7 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 12:12022535-12022535 12:11869601-11869601
8 MYH9 NM_002473.5(MYH9): c.4271A> G (p.Asp1424Gly) single nucleotide variant Likely pathogenic rs867593888 22:36688105-36688105 22:36292059-36292059
9 COL4A4 NM_000092.4(COL4A4): c.4217-15T> C single nucleotide variant Conflicting interpretations of pathogenicity rs200926310 2:227877028-227877028 2:227012312-227012312
10 CHEK2 NM_007194.4(CHEK2): c.1100del (p.Thr367fs) deletion Conflicting interpretations of pathogenicity rs555607708 22:29091857-29091857 22:28695869-28695869
11 FLNA NM_001110556.2(FLNA): c.7463C> A (p.Thr2488Asn) single nucleotide variant Uncertain significance rs909387820 X:153578106-153578106 X:154349738-154349738
12 MASTL NM_032844.4(MASTL): c.2523T> C (p.Asn841=) single nucleotide variant Uncertain significance rs886046961 10:27475351-27475351 10:27186422-27186422
13 MASTL NM_032844.4(MASTL): c.1703A> C (p.Asn568Thr) single nucleotide variant Uncertain significance rs761812157 10:27459591-27459591 10:27170662-27170662
14 MASTL NM_032844.4(MASTL): c.1415A> G (p.Glu472Gly) single nucleotide variant Uncertain significance rs139695329 10:27459303-27459303 10:27170374-27170374
15 MASTL NM_032844.4(MASTL): c.1355C> A (p.Ser452Tyr) single nucleotide variant Uncertain significance rs148839815 10:27459243-27459243 10:27170314-27170314
16 MASTL NM_032844.4(MASTL): c.346G> A (p.Gly116Arg) single nucleotide variant Uncertain significance rs886046957 10:27448569-27448569 10:27159640-27159640
17 MASTL NM_032844.4(MASTL): c.-170C> T single nucleotide variant Uncertain significance rs554557381 10:27444186-27444186 10:27155257-27155257
18 MASTL NM_032844.4(MASTL): c.-226G> A single nucleotide variant Uncertain significance rs566954562 10:27444130-27444130 10:27155201-27155201
19 MASTL NM_032844.4(MASTL): c.-254T> G single nucleotide variant Uncertain significance rs553530687 10:27444102-27444102 10:27155173-27155173
20 MASTL NM_032844.4(MASTL): c.-345T> C single nucleotide variant Uncertain significance rs886046954 10:27444011-27444011 10:27155082-27155082
21 MASTL NM_032844.4(MASTL): c.-346del deletion Uncertain significance rs886046953 10:27444010-27444010 10:27155081-27155081
22 CYCS NM_018947.5(CYCS): c.*1310G> C single nucleotide variant Uncertain significance rs550435948 7:25162010-25162010 7:25122391-25122391
23 CYCS NM_018947.5(CYCS): c.*1343A> G single nucleotide variant Uncertain significance rs868242183 7:25161977-25161977 7:25122358-25122358
24 CYCS NM_018947.5(CYCS): c.*4358G> C single nucleotide variant Uncertain significance rs886062233 7:25158962-25158962 7:25119343-25119343
25 CYCS NM_018947.5(CYCS): c.*4408A> C single nucleotide variant Uncertain significance rs768414867 7:25158912-25158912 7:25119293-25119293
26 CYCS NM_018947.5(CYCS): c.*4686C> G single nucleotide variant Uncertain significance rs886062231 7:25158634-25158634 7:25119015-25119015
27 CYCS NM_018947.5(CYCS): c.-80T> C single nucleotide variant Uncertain significance rs748044960 7:25164890-25164890 7:25125271-25125271
28 ANKRD26 NM_014915.2(ANKRD26): c.2559+10T> A single nucleotide variant Uncertain significance rs768668962 10:27326790-27326790 10:27037861-27037861
29 ANKRD26 NM_014915.2(ANKRD26): c.3367A> G (p.Asn1123Asp) single nucleotide variant Uncertain significance rs746125031 10:27324012-27324012 10:27035083-27035083
30 ANKRD26 NM_014915.2(ANKRD26): c.3940G> A (p.Glu1314Lys) single nucleotide variant Uncertain significance rs886046945 10:27317813-27317813 10:27028884-27028884
31 ANKRD26 NM_014915.2(ANKRD26): c.4808C> G (p.Thr1603Ser) single nucleotide variant Uncertain significance rs886046944 10:27301956-27301956 10:27013027-27013027
32 ANKRD26 NM_014915.2(ANKRD26): c.162C> T (p.Ala54=) single nucleotide variant Uncertain significance rs761866364 10:27389094-27389094 10:27100165-27100165
33 ANKRD26 NM_014915.2(ANKRD26): c.*8G> T single nucleotide variant Uncertain significance rs886046943 10:27294511-27294511 10:27005582-27005582
34 ANKRD26 NM_014915.2(ANKRD26): c.*704C> G single nucleotide variant Uncertain significance rs886046940 10:27293815-27293815 10:27004886-27004886
35 ANKRD26 NM_014915.2(ANKRD26): c.*1174C> G single nucleotide variant Uncertain significance rs886046938 10:27293345-27293345 10:27004416-27004416
36 CYCS NM_018947.5(CYCS): c.147C> T (p.Tyr49=) single nucleotide variant Uncertain significance rs375916000 7:25163592-25163592 7:25123973-25123973
37 CYCS NM_018947.5(CYCS): c.*248T> A single nucleotide variant Uncertain significance rs533205759 7:25163072-25163072 7:25123453-25123453
38 CYCS NM_018947.5(CYCS): c.*537C> T single nucleotide variant Uncertain significance rs532984462 7:25162783-25162783 7:25123164-25123164
39 CYCS NM_018947.5(CYCS): c.*2502T> C single nucleotide variant Uncertain significance rs886062243 7:25160818-25160818 7:25121199-25121199
40 CYCS NM_018947.5(CYCS): c.*2763T> C single nucleotide variant Uncertain significance rs886062241 7:25160557-25160557 7:25120938-25120938
41 CYCS NM_018947.5(CYCS): c.*2799T> G single nucleotide variant Uncertain significance rs558630511 7:25160521-25160521 7:25120902-25120902
42 CYCS NM_018947.5(CYCS): c.*2804C> T single nucleotide variant Uncertain significance rs886062240 7:25160516-25160516 7:25120897-25120897
43 CYCS NM_018947.5(CYCS): c.*3319C> T single nucleotide variant Uncertain significance rs886062237 7:25160001-25160001 7:25120382-25120382
44 CYCS NM_018947.5(CYCS): c.*3495G> A single nucleotide variant Uncertain significance rs147380544 7:25159825-25159825 7:25120206-25120206
45 ANKRD26 NM_014915.2(ANKRD26): c.-138C> G single nucleotide variant Uncertain significance rs886046950 10:27389393-27389393 10:27100464-27100464
46 ANKRD26 NM_014915.2(ANKRD26): c.50C> T (p.Ala17Val) single nucleotide variant Uncertain significance rs886046948 10:27389206-27389206 10:27100277-27100277
47 ANKRD26 NM_014915.2(ANKRD26): c.101C> T (p.Ala34Val) single nucleotide variant Uncertain significance rs368560982 10:27389155-27389155 10:27100226-27100226
48 ANKRD26 NM_014915.2(ANKRD26): c.452A> C (p.His151Pro) single nucleotide variant Uncertain significance rs752031374 10:27382357-27382357 10:27093428-27093428
49 ANKRD26 NM_014915.2(ANKRD26): c.789C> G (p.Asp263Glu) single nucleotide variant Uncertain significance rs777702991 10:27368042-27368042 10:27079113-27079113
50 ANKRD26 NM_014915.2(ANKRD26): c.948T> C (p.Asp316=) single nucleotide variant Uncertain significance rs569751156 10:27366396-27366396 10:27077467-27077467

Expression for Thrombocytopenia

Search GEO for disease gene expression data for Thrombocytopenia.

Pathways for Thrombocytopenia

Pathways related to Thrombocytopenia according to KEGG:

# Name Kegg Source Accession
1 Tight junction hsa04530

Pathways related to Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
10 11.65 ITGB3 ITGA2B ITGA2
12 11.46 ITGB3 ITGA2B ITGA2
13 11.42 ITGB3 ITGA2B GP9 GATA1
Show member pathways
15 11.38